

€ millions | 2006 | 2005 | % change |
Q3 Sales | 24.89 | 22.76 | 9% |
France, including overseas dependencies | 11.96 | 10.83 | 10% |
Subsidiaries (1) | 9.73 | 8.88 | 10% |
Distributors | 3.20 | 3.05 | 5% |
Cumulative sales at end September | 89.09 | 78.89 | 13% |
France, including overseas dependencies | 47.18 | 41.61 | 13% |
Subsidiaries (1) | 31.96 | 28.44 | 12% |
Distributors | 9.95 | 8.84 |
|
(1)Germany, Belgium, Italy, Spain and Portugal.
3rd quarter growth was in keeping with 2nd quarter growth.
In France, the increase in sales remained satisfactory (up 10%) and new patients continued to be attracted.
Even though subsidiary growth remained at a good level (up 10%), it was also more uneven: sales growth slowed down in Germany in a sluggish market, whereas Spain fully benefited from the successful integration of IPI.
The traditionally more volatile distributor segment slowed down as expected (up 5%) following two quarters of strong growth.
Cumulative growth at end September was 13% (of which 12% was organic). As forecast, full year growth should exceed 10% for the sixth year running.